Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk <i>Five</i> Study
Kwee Yong(CRUK Lung Cancer Centre of Excellence), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Louise Flanagan(University of Leeds), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Faith E. Davies(NYU Langone Health), Ceri Bygrave(Cardiff and Vale University Health Board), Holger W. Auner(University Hospital of Lausanne), Debbie Sherratt(University of Leeds), Sarah Brown(University of Leeds), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Martin Kaiser(Royal Marsden NHS Foundation Trust), Samantha Hinsley(University of Leeds), Gareth J. Morgan(Hywel Dda University Health Board), Stephen F. Hawkins(University of Liverpool), Ruth M. de Tute(St James's University Hospital), Jamie Cavenagh(St Bartholomew's Hospital), Neil Rabin(University College London)
Cited by 7
Related Papers
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k